135 related articles for article (PubMed ID: 17515767)
1. F-18 FDG PET as an imaging tool for detecting and staging metastatic basal-cell carcinoma.
Niederkohr RD; Gamie SH
Clin Nucl Med; 2007 Jun; 32(6):491-2. PubMed ID: 17515767
[No Abstract] [Full Text] [Related]
2. Metastatic malignant melanoma to the thyroid gland detected by FDG-PET imaging.
Basu S; Alavi A
Clin Nucl Med; 2007 May; 32(5):388-9. PubMed ID: 17452870
[No Abstract] [Full Text] [Related]
3. Positron emission tomography for basal cell carcinoma of the head and neck.
Fosko SW; Hu W; Cook TF; Lowe VJ
Arch Dermatol; 2003 Sep; 139(9):1141-6. PubMed ID: 12975155
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of (18)F-FDG PET/CT in recurrent basal cell carcinoma: Report of a case.
Ayala S; Perlaza P; Puig S; Prats E; Vidal-Sicart S
Rev Esp Med Nucl Imagen Mol; 2016; 35(2):124-6. PubMed ID: 26522004
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
7. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
8. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study.
Klein M; Freedman N; Lotem M; Marciano R; Moshe S; Gimon Z; Chisin R
Nuklearmedizin; 2000; 39(3):56-61. PubMed ID: 10834191
[TBL] [Abstract][Full Text] [Related]
9. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
10. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT Monitoring of Response to Programmed Death Protein 1 Blockade in Metastatic Basal Cell Carcinoma.
Jadvar H; In GK
Clin Nucl Med; 2021 Aug; 46(8):e436-e437. PubMed ID: 33512957
[TBL] [Abstract][Full Text] [Related]
12. Small bowel invagination caused by intestinal melanoma metastasis: unsuspected diagnosis by FDG-PET/CT imaging.
Strobel K; Skalsky J; Hany TF; Dummer R; Steinert HC
Clin Nucl Med; 2007 Mar; 32(3):213-4. PubMed ID: 17314600
[No Abstract] [Full Text] [Related]
13. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging.
Sarlis NJ; Gourgiotis L; Guthrie LC; Galen B; Skarulis MC; Shawker TH; Patronas NJ; Reynolds JC
Clin Nucl Med; 2003 Mar; 28(3):208-17. PubMed ID: 12592128
[TBL] [Abstract][Full Text] [Related]
14. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis.
King AD; Ma BB; Yau YY; Zee B; Leung SF; Wong JK; Kam MK; Ahuja AT; Chan AT
Br J Radiol; 2008 Apr; 81(964):291-8. PubMed ID: 18344274
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
16. Fluorodeoxyglucose positron emission tomography for melanoma staging: refining the indications.
Wagner JD
Ann Surg Oncol; 2006 Apr; 13(4):444-6. PubMed ID: 16491336
[No Abstract] [Full Text] [Related]
17. [The role of PET scan in the diagnosis of malignant melanoma].
Hunyadi J; Szakáll S; Gilde K; Bégány A; Esik O; Trón L; Galuska L; Ocsai H; Török L
Orv Hetil; 2002 May; 143(21 Suppl 3):1272-5. PubMed ID: 12077913
[TBL] [Abstract][Full Text] [Related]
18. Colonic adenomas detected by F-FDG PET.
Felig DM; Sedarat A; Agress H; Waintraub SE
Gastrointest Endosc; 2002 Nov; 56(5):734. PubMed ID: 12397286
[No Abstract] [Full Text] [Related]
19. [Positron emission tomography for the preoperative staging of esophageal carcinoma].
Junginger T; Kneist W; Schreckenberger M; Menzel C; Oberholzer K; Bartenstein P
Dtsch Med Wochenschr; 2002 Sep; 127(38):1935-41. PubMed ID: 12239652
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT Findings in Metastatic Pilomatrix Carcinoma.
Sengoz T; Avci N
Clin Nucl Med; 2020 Feb; 45(2):146-147. PubMed ID: 31833930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
